Docking study, Synthesis, Characterization and Preliminary cytotoxic evaluation of new 1,2,3,4-tetrahydroppyrimidine derivatives


  • Noor M. Mohammed Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq.



Antitumor, MCF-7, HRT-18, Semicarbazide, Dihydropyrimidine, Thiosemicarbazide, Docking study


Objective: This study resolved that1 these anew synthesized analogs1 may 1be embodied as1 an 1exploitable foundation of new 1anticancer1 1agents to competition breast 1cancer

Methods: By means of The crystal1 structure of Histone deacetylases (HDACs-8) with Vorinostat (SAHA) as 1a co-crystalized1 ligand 1was gained1 from 1the protein 1data-bank 1 (PDB 1code 4QA0) as a result 1of 1docking the compounds (V a,s, V b,s, V a,t and V b,t) give 1good docking 1scores compared1 to the standard. 1 Compounds (V a,s, V b,s, V a,t and V b,t) was synthesized1 by multistep procedures1 from the reaction of  intermediate derivatives (IV a,b) and the thiosemicarbazide or semicarbazide . The chemical1 structures1 of the1 target compounds11 and 1their intermediates1 were1 confirmed by 1FT-IR and1H 1NMR

Results: The in-vitro cytotoxicity1 assay (MTT assay) demonstrated1 that compounds1 V a,t and V b,t showed1 good inhibition 1ratios in Breast1 cancer cell line1 (MCF-7) and human colon adenocarcinoma (HRT-18) 1comparable with drug1 control Vorinostat (SAHA).

Conclusion: 1From the docking1 study, it was1 concluded1 that C=S moiety were very1 1successful to bind 1tightly to the zinc binding group of HDAC enzyme by making numerous 1interaction modes.


Baretti M, Azad NS. The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer. 2018;42(6):530-47.

Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harbor perspectives in biology. 2016;8(9):a019505.

Bunkar N, Pathak N, Lohiya NK, Mishra PK. Epigenetics: A key paradigm in reproductive health. Clinical and Experimental Reproductive Medicine. 2016;43(2):59.

Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27-36.

Manal M, Manish K, Sanal D, Selvaraj A, Devadasan V, Chandrasekar M. Novel HDAC8 inhibitors: A multi-computational approach. SAR and QSAR in Environmental Research. 2017;28(9):707-33.

Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, et al. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. Journal of Histochemistry & Cytochemistry. 2014;62(1):11-33.

Ruijter AJd, GENNIP AHv, Caron HN, Kemp S, KUILENBURG ABv. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal. 2003;370(3):737-49.

Zhou H, Wang C, Ye J, Chen H, Tao R. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors. Gene. 2017; 637:63-71.

Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. International journal of molecular sciences. 2017;18(7):1414.

Zwick V, Chatzivasileiou A-O, Deschamps N, Roussaki M, Simões-Pires CA, Nurisso A, et al. Aurones as histone deacetylase inhibitors: Identification of key features. Bioorganic & medicinal chemistry letters. 2014;24(23):5497-501.

Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent progress in histone deacetylase inhibitors as anticancer agents. Current medicinal chemistry. 2020;27(15):2449-93.

Yoon S, Kang G, Eom GH. HDAC inhibitors: therapeutic potential in fibrosis-associated human diseases. International journal of molecular sciences. 2019;20(6):1329.

Yu C, He F, Qu Y, Zhang Q, Lv J, Zhang X, et al. Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap. Bioorganic & Medicinal Chemistry. 2018;26(8):1859-68.

Brindisi M, Senger J, Cavella C, Grillo A, Chemi G, Gemma S, et al. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. European Journal of Medicinal Chemistry. 2018; 157:127-38.

Liu R, Wang J, Tang W, Fang H. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry. 2016;24(7):1446-54.

Manal M, Chandrasekar M, Priya JG, Nanjan M. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorganic chemistry. 2016; 67:18-42.

Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: Promising agents for breast cancer treatment. Bioorganic Chemistry. 2019; 91:103184.

Ding J, Liu J, Zhang Z, Guo J, Cheng M, Wan Y, et al. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities. Bioorganic Chemistry. 2020; 101:104023.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic acids research. 2000;28(1):235-42.

Saloutin V, Burgart YV, Kuzueva O, Kappe C, Chupakhin O. Biginelli condensations of fluorinated 3-oxo esters and 1, 3-diketones. Journal of Fluorine Chemistry. 2000;103(1):17-23.

K Hameed K, HS Hussain F. Ultrasound-Assisted Synthesis of Some New N-(Substituted Carboxylic Acid-2-yl)-6-Methyl-4-Substituted Phenyl-3, 4-Dihydropyrimidine-2 (1H)-One Carboxamides. Eurasian Journal of Science and Engineering. 2018;4(2).

Barbosa G, de Aguiar A. Synthesis of 1, 3, 4-Thiadiazole Derivatives and Microbiological Activities: A Review. Revista Virtual de Química. 2019;11(3):806-48.

González-Martínez D, Fernández-Sáez N, Cativiela C, Campos JM, Gotor-Fernández V. Development of Biotransamination Reactions towards the 3, 4-Dihydro-2 H-1, 5-benzoxathiepin-3-amine Enantiomers. Catalysts. 2018;8(10):470.

Yang F, Zhao N, Song J, Zhu K, Jiang C-s, Shan P, et al. Design, synthesis and biological evaluation of novel coumarin-based hydroxamate derivatives as histone deacetylase (hdac) inhibitors with antitumor activities. Molecules. 2019;24(14):2569.

Deyrieux AF, Wilson VG. In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line. Cytotechnology. 2007;54(2):77–83.

Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell Viability Assays. Assay Guid Man [Internet]. 2016;1–25. Available from:

Sarah S. Jabbar, Mohammed H.Mohammed. Coumarin based-histone deacetylase HADC inhibitors. Egyptian Journal of Chemistry. 2022;65(7)379-384.

Duraid Al-Amily, Mohammed H. Mohammed. Design, Synthesis and Cytotoxicity Study of Primary Amides as Histone Deacetylase Inhibitors. Iraqi J Pharm Sci. 2019.Vol.28(2) .

Othman M. Sagheer, Mohammed H. Mohammed, Jaafar S. Wadi, and Zaid O. Ibraheem. Studying the Cytotoxic Activity of Newly Designed and Synthesized HDAC 2100346.

Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. Journal of medicinal chemistry. 2003;46(24):5097-116.




How to Cite

Mohammed, N. M. . (2022). Docking study, Synthesis, Characterization and Preliminary cytotoxic evaluation of new 1,2,3,4-tetrahydroppyrimidine derivatives. Journal of Contemporary Medical Sciences, 8(5), 329–336.